16 Nov Effect of Second Generation Drug Eluting Stents on Cardiovascular Events

MedicalResearch.com Interview with:
Marco Valgimigli, MD, PhD
Associate Professor of Medicine
Erasmus MC, Thoraxcenter,
Rotterdam The Netherlands

Medical Research: What is the background for this study? What are the main findings?

Dr. Valgimigli: Drug-Eluting Stents are regarded as more thrombogenic devices as compared to Bare Metal Stents. We have pooled all available datasets comparing a specific second generation Drug-Eluting Stent, namely cobalt chromium everolimus eluting stent (co-Cr EES) versus Bare Metal Stents and found that cardiac mortality along with all other non-fatal endpoints investigated, including myocardial infarction or stent thrombosis were reduced after co-Cr EES.

Medical Research: What should clinicians and patients take away from your report?

Dr. Valgimigli: That Drug-Eluting Stents do not necessarily mean a more thrombogenic device than Bare Metal Stents.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Valgimigli: We should further investigate if Drug-Eluting Stents can tolerate a short or very short of dual anti-platelet therapy similar to Bare Metal Stents.

Citation:

Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g6427 (Published 05 November 2014) Cite this as: BMJ 2014;349:g6427

Last Updated on January 2, 2015 by Marie Benz MD FAAD